- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT00457418
High-Dose PEG-Intron Pharmacokinetic Study in Patients With Melanoma (Study P04831 AM2)
A Pharmacokinetic Study of PEG-Intron, Administered Weekly in Subjects With High-Risk Melanoma
Descripción general del estudio
Tipo de estudio
Inscripción (Actual)
Fase
- Fase 1
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Subjects at least 18 years of age, of either sex, and of any race.
- Cytologically or histologically-confirmed melanoma, arising from a cutaneous or unknown site of origin, at Stages IIB, IIC, IIIA, IIIB, IIIC according to the American Joint Committee on Cancer (AJCC) 2001 guidelines.
- Adequate hepatic, renal and bone marrow function within 4 weeks prior to initiation of study treatment.
- Subjects presenting with synchronous primary and regional melanoma must have had adequate surgical margins surrounding the primary lesion.
- Full lymphadenectomy must be performed within 90 days prior to initiation of study treatment.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Give informed consent according to International Conference on Harmonisation - Good Clinical Practice (ICH-GCP) and national/local policy.
- Be able to adhere to dose and visit schedules.
- Female subjects of childbearing potential must be using a medically accepted method of birth control prior to Screening and agree to continue its use during the study or be surgically sterilized.
- Female subjects of childbearing potential must have a negative serum pregnancy test at Screening.
Exclusion Criteria:
- Female subjects who are pregnant, intend to become pregnant, or are breastfeeding.
- Previous treatment with interferon alpha, chemotherapy or immunotherapy for melanoma.
- Ocular melanoma, or melanoma of the mucous membranes.
- Evidence of distant or non-regional lymph node metastases.
- In-transit melanoma, even if the lesion has been resected.
- Disease that cannot be completely surgically resected.
- Lack of recovery from recent surgery.
- Prior malignancy within the past 5 years, except surgically cured squamous cell carcinoma of the skin, successfully resected early stage cutaneous melanoma, or cervical carcinoma in situ.
- Severe cardiovascular disease.
- Thyroid dysfunction not responsive to therapy.
- Uncontrolled diabetes mellitus (in the opinion of the investigator).
- Active autoimmune disease.
- Active and/or uncontrolled infection.
- History of seropositivity for human immunodeficiency virus (HIV).
- Pre-existing psychiatric condition.
Clinical diagnosis of substance abuse of one or more of the following drugs within the following timeframes (excluding time spent in detoxification, hospitalization or incarceration):
- Alcohol, intravenous drug use, inhalational, psychotropics, narcotics, cocaine, prescription or over-the-counter drugs: within 1 year of the Screening visit.
- Methadone, buprenorphine hydrochloride (HCl), and/or butorphanol tartrate: within 1 year of Screening visit, unless subject has drug screen negative for other (non-narcotic) drugs documented in the past year and repeated negative within 2 months of Screening visit.
- Multi-drug abuse (2 or more substances in 16a and 16b): within 3 years of Screening visit.
Marijuana:
- If historic use is deemed excessive by the principal investigator (or medically qualified individual), or is interfering with the subject's life, then the subject is not eligible and should not be screened.
- If marijuana use is not deemed excessive by principal investigator and does not interfere with life, subject must discontinue any current use of marijuana prior to entry into study.
- Medical condition requiring chronic systemic corticosteroids.
- Known allergy to the drug substance or any of the excipients in the PEG-Intron formulation.
- Any situation or condition that, in the opinion of the investigator, may interfere with optimal participation in the study.
- Use of any investigational drugs within 30 days of study entry.
- Participation in other clinical studies of investigational treatments.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: No aleatorizado
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
---|---|
Experimental: PEG-Intron
6 ug/kg/week, SC (first 8 weeks) 3 ug/kg/week, SC (252 weeks [weeks 9-260], maintenance) |
Otros nombres:
|
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Area Under the Curve (AUC) of PEG-Intron at 12 Weeks
Periodo de tiempo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
AUC was defined as the actual body exposure to drug after administration of a dose of the drug.
|
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Maximum Serum Concentration (Cmax) of PEG-Intron at 12 Weeks
Periodo de tiempo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Cmax was defined as observed maximum plasma concentration.
|
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Average Concentration Within the Dosing Interval (Cavg) of PEG-Intron at 12 Weeks
Periodo de tiempo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Cavg was defined as average plasma concentration.
|
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Minimum Serum Concentration (Cmin) of PEG-Intron at 12 Weeks
Periodo de tiempo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Cmin was defined as observed minimum plasma concentration.
|
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Observed Time to Achieve Cmax (Tmax) of PEG-Intron at 12 Weeks
Periodo de tiempo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Tmax was defined as time of maximum plasma concentration.
|
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Apparent Clearance(CL/F) of PEG-Intron at 12 Weeks
Periodo de tiempo: Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
CL/F was defined apparent clearance - the volume of plasma in the vascular compartment cleared of drug per unit of time and per kilogram of body weight by the processes of metabolism and excretion.
|
Predose, and 24, 48, 72, 96, and 168 hours postdose at 12 weeks
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
---|---|---|
Number of Participants Who Experienced an Adverse Event (AE)
Periodo de tiempo: Entire study duration (up to 5 years)
|
An adverse event (AE) was defined as any untoward medical occurrence or unfavorable and unintended sign in a subject administered a pharmaceutical product, biologic (at any dose), or medical device, whether or not considered related to the use of that product.
|
Entire study duration (up to 5 years)
|
Colaboradores e Investigadores
Patrocinador
Publicaciones y enlaces útiles
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Actual)
Finalización del estudio (Actual)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Estimar)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- P04831
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .
Ensayos clínicos sobre PEG-Intron
-
Brooke Army Medical CenterT.R.U.E. Research FoundationTerminado
-
Merck Sharp & Dohme LLCTerminadoInfecciones por VIH | SIDA
-
University of PittsburghNational Cancer Institute (NCI)Terminado
-
Merck Sharp & Dohme LLCTerminado
-
Fundación de Investigación Biomédica - Hospital...Haematology Service,Desconocido
-
Merck Sharp & Dohme LLCTerminado
-
Louisiana State University Health Sciences Center...Schering-PloughTerminado
-
Merck Sharp & Dohme LLCTerminado
-
PharmaEssentiaTerminadoInfección crónica por el virus de la hepatitis CCorea, república de, Taiwán, Porcelana
-
Virginia Commonwealth UniversityOrtho Biotech, Inc.Terminado